Current and Future Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Interact with an expert during this 1-hour, CME-certified live meeting examining recent advances and current best practices in the use of immune checkpoint inhibitors for treating gastroesophageal cancers. Register today!


  • Overview of the evolving therapeutic landscape in gastroesophageal cancers
  • Esophagogastric biology and immunotherapy targets
  • Current understanding and practical guidance surrounding biomarkers for immune therapy in gastroesophageal cancers (MSI/MMR, PD-L1 expression/CPS, tumor mutational burden [TMB], and more)
  • Tumor-specific case discussions of immunotherapy usein gastroesophageal cancers
    • Esophageal cancer
    • Gastric cancer or gastroesophageal junction cancer
  • Practical guidance on managing irAEs in gastroesophageal cancer patients
  • Final thoughts and audience Q&A session


Date / Time
Event Details


Program Director
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Program Director
Zev A. Wainberg, MD

James M. Cleary, MD, PhD

Assistant Professor of Medicine
Harvard Medical School
Associate Director of Clinical Research
Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Steve Maron, MD

Assistant Attending
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD

Assistant Professor of Medicine
Weill Cornell Medical College
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners to integrate immune checkpoint inhibitors into the treatment of patients with advanced gastro-esophageal cancers.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with advanced gastro-esophageal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate available and emerging biomarkers of response to identify patients with advanced gastro-esophageal cancers most likely to benefit from ICI therapy
  • Apply clinical trial evidence to manage patients with advanced gastro-esophageal cancers in the context of evolving single-agent and ICI-based combination strategies
  • Incorporate enrollment of appropriate patients on clinical trials investigating ICI–based therapy as part of clinical care strategies for patients with advanced gastro-esophageal cancers
  • Identify and manage irAEs in gastro-esophageal cancer patients receiving ICI therapy


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.